EGFR and neoplasm: This knowledge promoted the investigation of EGFR inhibitor gefitinib (ZD1839, Iressa) along with ETA antagonist ZD4054, which revealed an enhanced efficacy, resulting in partial or complete tumour regression of ovarian carcinoma xenografts followed by decreased vascularisation, VEGF, MAPK, EGFR, matrix metalloproteinase-2 (MMP-2) and Ki-67 [502].